Format

Send to

Choose Destination
Curr Oncol Rep. 2016 Sep;18(9):57. doi: 10.1007/s11912-016-0542-9.

Evolving Immunotherapy Approaches for Renal Cell Carcinoma.

Author information

1
Section of Medical Oncology, Department of Medicine, Yale Cancer Center, 333 Cedar Street, PO Box 208028, New Haven, 06510, CT, USA.
2
Section of Medical Oncology, Department of Medicine, Yale Cancer Center, 333 Cedar Street, PO Box 208028, New Haven, 06510, CT, USA. Harriet.Kluger@yale.edu.

Abstract

Metastatic renal cell carcinoma (mRCC) continues to be associated with high rates of morbidity and mortality. Renal cell carcinoma (RCC) is typically resistant to cytotoxic chemotherapy, and while targeted therapies have activity and prolong progression-free and overall survival, responses are usually not durable. Modulating the immune system with cytokine therapy, vaccine therapy, cell therapy, and checkpoint inhibitors offers hope of prolonged survival. Standard and emerging immune therapy approaches and combinations of immune therapies and other modalities are reviewed.

KEYWORDS:

Adoptive cell therapy; Cytokines; Immune checkpoint inhibitors; Immunotherapy; Renal cell carcinoma; Vaccine therapy

PMID:
27475806
DOI:
10.1007/s11912-016-0542-9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center